Compare RBKB & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | ANIK |
|---|---|---|
| Founded | 1860 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.9M | 200.9M |
| IPO Year | 2018 | 1996 |
| Metric | RBKB | ANIK |
|---|---|---|
| Price | $12.48 | $21.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 203.3K | 88.4K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 215.00 | 80.16 |
| EPS | ★ 0.20 | N/A |
| Revenue | $2,984,000.00 | ★ $112,819,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | $62.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.41 | $8.22 |
| 52 Week High | $17.99 | $22.88 |
| Indicator | RBKB | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 31.68 | 71.05 |
| Support Level | $11.63 | $14.13 |
| Resistance Level | $12.63 | N/A |
| Average True Range (ATR) | 0.33 | 1.23 |
| MACD | 0.05 | 0.44 |
| Stochastic Oscillator | 73.58 | 79.76 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank, which is a New York-chartered stock savings bank. It provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management. The Bank's primary business activity is accepting deposits from the general public and using those funds together with borrowings, to originate commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and indirect automobile loans, and to purchase one- to four-family residential real estate loans and investment securities.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.